Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia

Blood

Volumn 114, Issue 24, 2009, Pages 4933-4938

  Rosti, Gianantonio ^a   Palandri, Francesca ^a   Castagnetti, Fausto ^a   Breccia, Massimo ^b   Levato, Luciano ^c   Gugliotta, Gabriele ^a   Capucci, Adele ^d   Cedrone, Michele ^e   Fava, Carmen ^f   Intermesoli, Tamara ^g   Cambrin, Giovanna Rege ^f   Stagno, Fabio ^h   Tiribelli, Mario ⁱ   Amabile, Marilina ^a   Luatti, Simona ^a   Poerio, Angela ^a   Soverini, Simona ^a   Testoni, Nicoletta ^a   Martinelli, Giovanni ^a   Alimena, Giuliana ^b   Pane, Fabrizio ^j   Saglio, Giuseppe ^f   Baccarani, Michele ^a   more..

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c PUGLIESE CIACCIO HOSPITAL   (Italy)

^d SPEDALI CIVILI   (Italy)

^e SAN GIOVANNI ADDOLORATA HOSPITAL   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

^g OSPEDALI RIUNITI   (Italy)

^h UNIVERSITY OF CATANIA   (Italy)

ⁱ UNIVERSITY OF UDINE   (Italy)

^j UNIVERSITY OF NAPLES FEDERICO II   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NILOTINIB; TRIACYLGLYCEROL LIPASE; 4 METHYL N (3 (4 METHYLIMIDAZOL 1 YL) 5 (TRIFLUOROMETHYL)PHENYL) 3 ((4 PYRIDIN 3 YLPYRIMIDIN 2 YL)AMINO)BENZAMIDE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; PYRIMIDINE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BONE MARROW SUPPRESSION; BONE PAIN; CANCER GRADING; CANCER GROWTH; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; DRY EYE; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NEUTROPENIA; PANCREATITIS; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; STOMACH PAIN; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; ADOLESCENT; DRUG EFFECT; GENETICS; MIDDLE AGED; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PYRIMIDINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 73949145209     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-07-232595     Document Type: Article

References (48)

1. Druker BJ, Sawyers CL, Kantarjian H, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031-1037.
2. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008;112(13):4808-4815.
3. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108(6):1809-1820.
4. Hehlmann R, Hochhaus A, Baccarani M on behalf of the European LeukemiaNet. Chronic myeloid leukemia. Lancet. 2007;370(9584):342-350.
5. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1004.
6. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular response to imatinib or interferon alpha plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349(15):1423-1432.
7. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-2417.
8. O'Brien SG, Guilhot F, Goldman J, et al. International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM) [abstract]. Blood. 2008;112(11):76. Abstract 186.
9. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009;23(6):1054-1061.
10. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26(20):3358- 3363.
11. Kantarjian HM, Talpaz M, O'Brien S, et al. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood. 2006;108(6):1835-1840.
12. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukemia. Lancet Oncol. 2007;8(11):1018-1029.
13. Apperley JF. Part II: management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 2007;8(12):1116-1129.
14. Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med. 2006;145(12):913-923.
15. Hochhaus A, Erben P, Ernst T, Mueller MC. Resistance to targeted therapy in chronic myelogenous leukemia. Semin Hematol. 2007;44(1 suppl 1):S15-S24.
16. O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007;110(7):2242-2249.
17. Quintas-Cardama A, Cortes J. Molecular biology of BCR-ABL1-positive chronic myeloid leukemia. Blood. 2009;113(8):1619-1630.
18. Bocchia M, Ippoliti M, Gozzetti A, et al. CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate. Leukemia. 2008;22(2):426-428.
19. Kavalerchik E, Goff D, Jamieson CHM. Chronic myeloid leukemia stem cells. J Clin Oncol. 2008;26(17):2911-2915.
20. Valent P. Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management and therapy of the disease. Br J Haematol. 2008;142(3):361-378.
21. Jiang X, Zhao Y, Smith C, et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapy. Leukemia. 2007;21(5):926-935.
22. Bhatia R, Holtz M, Niu N, et al. Persistence of hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood. 2003;101(12):4701-4707.
23. Elrick LJ, Jorgensen HG, Mountford JC, Holyoake TL. Punish the parent not the progeny. Blood. 2005;105(5):1862-1866.
24. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305(5682):399-401.
25. Weisberg E, Manley PW, Breitentein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant BCR-ABL. Cancer Cell. 2005;7(2):129-141.
26. Golemovic M, Verstovsek S, Giles F, et al. AMN107, a novel aminopyrimidine inhibitor of BCR-ABL, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res. 2005;11(13):4941-4947.
27. Yokota A, Kimura S, Masuda S et al. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph leukemia cells in central nervous system, and cyclosporine A augments its in vivo activity. Blood. 2007;109(1):306-314.
28. Puttini M, Coluccia AML, Boschelli F, et al. In vitro and in vivo activity of SKI-606, a novel src-abl inhibitor, against imatinib-resistant BCR-ABL neoplastic cells. Cancer Res. 2006;66(23):11314-11322
29. Talpaz M, Shah PS, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354(24):2531- 2541.
30. Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008;22(6):1200- 1206.
31. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354(24):2542-2551.
32. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2008;110(10):3540-3546.
33. O'Hare T, Walters DK, Stoffregen EP et al. In vitro activity of Bcr-ABl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant abl kinase domain mutants. Cancer Res. 2005;65(11):4500-4505.
34. Rosti G, Castagnetti F, Poerio A, et al. High and early rates of cytogenetic and molecular response with nilotinib 800 mg daily as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: results of a phase 2 trial of the GIMEMA CML working party [abstract]. Blood. 2008;112(11):73-74. Abstract 181.
35. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984;63(4):789-799.
36. Hasford J, Pfirmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst. 1998;90(11):850-858.
37. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28-37.
38. Marzocchi G, Luatti S, Amabile M. et al. A prospective study in chronic myeloid leukemia (CML) patients: FISH is effective as conventional cytogenetics for definition of cytogenetic response to imatinib. Correlation with molecular response (a GIMEMA CML WP study). Haematologica. 2007;92(suppl 3):45.
39. Reinhold U, Hennig E, Leiblein S, Niederwieser D, Deininger MW. FISH for BCR-ABL on inter-phases of peripheral blood neutrophils but not of unselected white bone marrow cells in CML patients treated with imatinib. Leukemia. 2003;17(10):1925-1929.
40. Branford S, Cross NC, Hochhaus A, et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia. 2006;20(11):1925-1930.
41. Müller MC, Saglio G, Lin F, et al. An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR. Haematologica. 2007;92(7):970-973.
42. Branford S, Fletcher L, Cross NC, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008;112(8):3330-3338.
43. Müller MC, Erben P, Saglio G, et al. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia. 2008;22(1):96-102.
44. A'Hern RP. Sample size tables for exact single-stage phase II designs. Stat Med. 2001;20(6):859-866.
45. Kantarjian HM, Giles F, Bhalla KN, et al. Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study [abstract]. Blood. 2008;112(11):1112. Abstract 3238.
46. Cortes J, O'Brien S, Jones D, et al. Efficacy of nilotinib (formely AMN107) in patients with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP) [abstract]. Blood. 2008;112(11):170. Abstract 446.
47. White DL, Saunders VA, Dang P, et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood. 2006;108(2):697-704.
48. Mountford J, Davies A, Jordanides NE, et al. Nilotinib concentrations in cell lines and CD34+ cells is not mediated by active uptake or efflux by major drug transporters [abstract]. Blood. 2008;112(11):3205. Abstract 3205.